An Integrated Preclinical Platform for GBM Immunotherapy Development
This white paper presents a strategic platform for leveraging patient-derived xenografts, humanized models, and predictive technologies to identify, optimize, and translate promising immunotherapeutic strategies. By integrating tumor mutational burden analysis, HLA profiling, and multi-modal endpoint assessment, researchers can design rational combination therapies that address GBM’s complex immune landscape with unprecedented precision.
Download White Paper
Back to Feed